Advertisement

Toward a MERS Vaccine

Researchers generate an infectious cDNA clone of the Middle East respiratory syndrome coronavirus genome that could inform vaccine design.

By | September 12, 2013

MERS coronavirusNIAIDOn Saturday (September 7), the World Health Organization noted four additional laboratory-confirmed cases of the Middle East respiratory syndrome (MERS) in Saudi Arabia, bringing the total number of infections to 114, including 54 deaths. As scientists continue to investigate the deadly coronavirus (CoV) the causes MERS, researchers from the Spanish National Center for Biotechnology (CNB) have constructed a full-length infectious cDNA clone of the MERS-CoV genome in a bacterial artificial chromosome, which they said provides “a reverse genetics system to study the molecular biology of the virus and to develop attenuated viruses as vaccine candidates.” The CNB team’s results appeared online in mBio this week (September 10).

From the cDNA clone, coronavirus expert Luis Enjuanes of CNB and his colleagues generated recombinant MERS-CoVs lacking the ability to cause disease, but capable of invading a cell and replicating their genetic material. The team then engineered one of these mutant viruses to lack the structural envelope protein gene, making it replication-competent but propagation-defective and therefore, “a safe and promising vaccine candidate to prevent MERS-CoV infection,” the authors noted in their paper.

“The injected vaccine will only replicate in a reduced number of cells and produce enough antigen to immunize the host,” Enjuanes said in a statement.

The Spanish team isn’t the only group pursuing MERS vaccines—Rockville, Maryland’s Novavax and Aurora, Colorado-based Greffex have both reported on candidates that target the CoV’s major surface spike protein. Despite these efforts, however, The Canadian Press (CP) notes that even the most promising MERS vaccine candidates would take at least five years to become market-ready. “There’s a long way to go from showing in a research laboratory that you’ve got a potential candidate vaccine to actually producing a bottle of that vaccine that is going to be used or stockpiled,” Baylor College of Medicine’s Peter Hotez told the CP.

Advertisement
The Scientist
The Scientist

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo
Advertisement
LI-COR
LI-COR

Popular Now

  1. Neanderthal-Human Hybrid Unearthed
  2. Extra DNA Base Discovered
    The Nutshell Extra DNA Base Discovered

    An epigenetic variant of cytosine is stable in the genomes of living mice, suggesting a possible expansion of the DNA alphabet.

  3. Opinion: Too Many Mitochondrial Genome Papers
  4. Next Generation: Smart Insulin Patch
Advertisement
BioTek
BioTek
Advertisement
The Scientist